ALT NHEJ is a therapeutic target in hormone therapy resistant ER/PR/HER plus and ER/PR/HER-breast cancers

被引：0
|
作者：
Tobin, Lisa A. [1 ]
Chumsri, Saranya [1 ]
Staats, Paul [1 ]
Brodie, Angela [1 ]
Tomkinson, Alan [1 ]
Rassoo, Feyruz [1 ]
机构：
[1] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5495
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of the sensitivity to endocrine therapy of PR plus /ER- patients and ER plus /PR- patients with HER2+breast cancer
    Hao, X.
    Liu, Y.
    Hui, R.
    Zhang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Therapeutic Benefit of Chemotherapy and Hormone Therapy Among Estrogen Response Signature-Positive ER+/PR+/HER2-Breast Cancers
    Sandhu, Rupninder
    Parker, Joel
    Anders, Carey
    Coleman, William
    FASEB JOURNAL, 2015, 29
  • [3] QuantiGene 2.0 Assay for ER, PR and HER2 RNA Levels Is a Useful Adjunctive for the Evaluation of ER, PR and HER2 in Breast Cancer
    Lee, A.
    Chae, B. J.
    Song, B. J.
    Jung, S. S.
    Yim, H. W.
    CANCER RESEARCH, 2009, 69 (24) : 758S - 758S
  • [4] The molecular pathology of ER, PR HER2 negative breast cancers: finding novel biomarkers
    Reis-Filho, J. S.
    Tutt, A.
    EJC SUPPLEMENTS, 2008, 6 (07): : 166 - 166
  • [5] Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2-breast tumours
    Ghosh, Arnab
    Chaubal, Rohan
    Das, Chitrarpita
    Parab, Pallavi
    Das, Subrata
    Maitra, Arindam
    Majumder, Partha P.
    Gupta, Sudeep
    Biswas, Nidhan K.
    COMMUNICATIONS BIOLOGY, 2025, 8 (01)
  • [6] Branched-chain Assay for ER, PR, and HER2 RNA Levels is a Useful Adjunct in the Evaluation of ER, PR, and HER2 in Breast Cancer
    Yim, Hyeon Woo
    Song, Byung Joo
    Jung, Sang Seol
    Kim, Hyun-Joo
    Choi, Yeong-Jin
    Lee, Kyo-Young
    Lee, Ahwon
    JOURNAL OF BREAST CANCER, 2010, 13 (03) : 267 - 274
  • [7] Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes
    Wu Ding
    Dengfeng Ye
    Haifeng Chen
    Yingli Lin
    Zhian Li
    Chuanjian Tu
    Breast Cancer, 2024, 31 : 295 - 304
  • [8] Differential Responses to Hormone Therapy Among ER+/PR+/HER2-Breast Cancers That Differentially Express the Estrogen Response Signature
    Sandhu, Rupninder
    Parker, Joel
    Anders, Carey
    Coleman, William
    FASEB JOURNAL, 2015, 29
  • [9] Evaluation of Hormone Receptor Status (ER/PR/HER2-neu) in Breast Cancer in Pakistan
    Pervaiz, Fahad
    Rehmani, Sahrish
    Majid, Sana
    Anwar, Hina
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2015, 65 (07) : 747 - 752
  • [10] Personalizing Breast Cancer Staging by the Inclusion of ER, PR, and HER2
    Bagaria, Sanjay P.
    Ray, Partha S.
    Sim, Myung-Shin
    Ye, Xing
    Shamonki, Jaime M.
    Cui, Xiaojiang
    Giuliano, Armando E.
    JAMA SURGERY, 2014, 149 (02) : 125 - 129
12345